Growing community of inventors

Dresden, Germany

Rudolf Fahrig

Average Co-Inventor Count = 3.43

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 28

Rudolf FahrigJorg-Christian Heinrich (2 patents)Rudolf FahrigDieter Lohmann (1 patent)Rudolf FahrigJoerg-Christian Heinrich (1 patent)Rudolf FahrigHenrik Dieks (1 patent)Rudolf FahrigAndreas Rolfs (1 patent)Rudolf FahrigNicole Heinze (1 patent)Rudolf FahrigKurt Eger (1 patent)Rudolf FahrigJanek Teubner (1 patent)Rudolf FahrigMatthias Klemm (1 patent)Rudolf FahrigGeorg Krupitza (1 patent)Rudolf FahrigMartin Fuhrer (1 patent)Rudolf FahrigAngela Steinkamp-Zucht (1 patent)Rudolf FahrigJörg-Christian Heinrich (0 patent)Rudolf FahrigRudolf Fahrig (4 patents)Jorg-Christian HeinrichJorg-Christian Heinrich (2 patents)Dieter LohmannDieter Lohmann (9 patents)Joerg-Christian HeinrichJoerg-Christian Heinrich (2 patents)Henrik DieksHenrik Dieks (1 patent)Andreas RolfsAndreas Rolfs (1 patent)Nicole HeinzeNicole Heinze (1 patent)Kurt EgerKurt Eger (1 patent)Janek TeubnerJanek Teubner (1 patent)Matthias KlemmMatthias Klemm (1 patent)Georg KrupitzaGeorg Krupitza (1 patent)Martin FuhrerMartin Fuhrer (1 patent)Angela Steinkamp-ZuchtAngela Steinkamp-Zucht (1 patent)Jörg-Christian HeinrichJörg-Christian Heinrich (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Resprotect Gmbh (4 from 5 patents)


4 patents:

1. 9181199 - Uracil derivatives and use thereof

2. 8492537 - Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy

3. 7713948 - Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs

4. 6589941 - Utilization of 5′ substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/9/2025
Loading…